|
⚲
|
| Keyboard |
| Matrix Private Capital Group LLC
✚
|
|
|---|---|
| CRD # | 285531 |
| SEC # | 801-108654 |
| CIK # | 0001906866, 0001410830 |
| AUM | 561.0 M (2026-03-27) |
| Employees | 8 (62% Investors, 0% Brokers) |
| Phone | 312-736-9572 |
| Address | 500 West Madison Street Chicago, IL 60661 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| In the News | |
|---|---|
| Wed, 29 Jul 2026 | Matrix Private Capital Group LLC Makes New $2.49 Million Investment in JPMorgan Chase & Co. $JPM — MarketBeat |
| Sun, 26 Jul 2026 | Matrix Private Capital Group LLC Acquires Shares of 4,393 International Business Machines Corporation $IBM — MarketBeat |
| Sun, 26 Jul 2026 | Matrix Private Capital Group LLC Takes Position in Taiwan Semiconductor Manufacturing Company Ltd. $TSM — MarketBeat |
| Sun, 26 Jul 2026 | Matrix Private Capital Group LLC Acquires New Position in Blackstone Inc. $BX — MarketBeat |
| Sun, 26 Jul 2026 | Matrix Private Capital Group LLC Acquires New Position in Merck & Co., Inc. $MRK — MarketBeat |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| AURA Biosciences Inc | 0.0 | ||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| Other | Matrix Novva LLC | [2026-03-27] | 12.3 M | 15.1 M |
| Offered $15,150,000 · Filed 2025-04-21 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining $2,865,000 · Duration One year or less · Net Assets $5,000,001 - $25,000,000 | ||||
| Other | Matrix Denali LP | [2024-03-26] | 10.4 M | 6.1 M |
| Offered $10,400,000 · Filed 2023-09-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Duration One year or less · Net Assets $5,000,001 - $25,000,000 | ||||
| Other | Matrix Veritas LP | [2020-03-30] | 4.9 M | 0.1 M |
| Filed 2020-03-10 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $50,000 · Remaining Indefinite · Duration One year or less · Net Assets $1 - $5,000,000 | ||||
| Other | Matrix Banff LP | [2019-03-28] | 5.4 M | 10.5 M |
| Offered $5,365,000 · Filed 2018-10-10 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $30,000 · Duration One year or less · Net Assets $5,000,001 - $25,000,000 | ||||
| HF | Matrix Highline LP | 2018-01-26 | 10.4 M | |
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 84 | 67.7 |
| (b) Individuals (high net worth individuals) | 124 | 382.9 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 4 | 31.9 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 10 | 78.6 |
| (n) Other | 0 | 0.0 |
| Total | 827 | 561.0 |
| By Discretionary | ||
| Discretionary | 827 | 561.0 |
| Non-Discretionary | 0 | 0.0 |
| Total | 827 | 561.0 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.9 | |
| United States Persons | 560.0 | |
| Total | 827 | 561.0 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Matthew Rubin | Director | 12 | 2 | |
| Richard Fuld | Director, Executive Officer | 5 | 2 | |
| Richard Kravitz | Director, Executive Officer | 4 | 2 | |
| Robert Wohl | Executive Officer | 2 | 2 | |
| Scott Weissman | Director | 2 | 2 | |
| Marc Scheuer | Director, Executive Officer | 4 | 1 | |
| Charlie Wemyss | Executive Officer | 1 | 1 | |
| Lance Bryan | Director | 1 | 1 | |
| Charles Wemyss | Director | 1 | 1 | |
| Seth Scher | Executive Officer | 1 | 1 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001410830] | |
| 3 | [0001410830] | |
| 4 | [0001410830] | |
| SC 13D | [0001410830] | |
| SC 13G | [0001410830] | |
| 13F-HR | [0001906866] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional, Retail |
| Fund Types | Hedge Fund |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Matrix Capital Management Company LP | |
| Aura Biosciences Inc | |
| GOEL David E | |
| Zentalis Pharmaceuticals Inc | |
| Adaptive Biotechnologies Corp |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
|
2025-12-15 | Sell | 7,500,000 | $1.33 | 9,975,000 |
|
Aura Biosciences Inc AURA
Common Stock, par value $0.00001 per share (Common Stock)
|
2023-11-09 | Buy | 1,560,000 | $9.00 | 14,040,000 |
|
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
|
2023-06-20 | Buy | 4,760,000 | $22.66 | 107,861,600 |
|
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
|
2022-12-05 | Buy | 1,250,000 | $12.00 | 15,000,000 |
|
Aura Biosciences Inc AURA
Common Stock
|
2021-11-02 | Buy | 1,785,000 | $14.00 | 24,990,000 |
|
Aura Biosciences Inc AURA
Series E Convertible Preferred Stock · derivative
|
2021-11-02 | Conversion | 2,327,870 | $0.00 | |
|
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
|
2021-11-02 | Conversion | 2,327,870 | ||
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-10 | Sell | 30,268 | $42.38 | 1,282,758 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-10 | Sell | 25,732 | $41.47 | 1,067,106 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-09 | Sell | 34,302 | $41.16 | 1,411,870 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-09 | Sell | 215,698 | $40.42 | 8,718,513 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 71,194 | $41.21 | 2,933,905 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 234,295 | $38.22 | 8,954,755 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 75,000 | $39.22 | 2,941,500 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 33,600 | $39.97 | 1,342,992 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2021-03-08 | Sell | 85,911 | $41.62 | 3,575,616 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2020-07-20 | Sell | 2,000,000 | $40.00 | 80,000,000 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2020-01-24 | Conversion | 2,217,101 | $26.50 | 58,753,176 |
|
Adaptive Biotechnologies Corp ADPT
Common Stock
|
2019-07-01 | Conversion | 84,359 | ||
|
Adaptive Biotechnologies Corp ADPT
Series E-1 Convertible Preferred Stock · derivative
|
2019-07-01 | Conversion | 5,893,716 | $0.00 | |
| showing 20 of 26 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Hyperion Capital Advisors LP
✚
|
NY | 581.3 M |
|
Able Wealth Management LLC
✚
|
NJ | 579.5 M |
|
Valueworks LLC
✚
|
NY | 577.3 M |
|
Capital Markets IQ LLC
✚
|
571.4 M | |
|
Loom Capital Management LLC
✚
|
NY | 570.8 M |
|
Bulldog Investors LLP
✚
|
NJ | 561.0 M |
|
Empirical Asset Management LLC
✚
|
MA | 560.0 M |
|
Snider Retirement Strategies Inc
✚
|
WA | 549.7 M |
|
Cable Car Capital LP
✚
|
CA | 548.3 M |
|
Aristides Capital LLC
✚
|
KY | 541.4 M |